Category - Feature

Feature

Inventiva targeting MASH at its biological roots

By Melane Sampson Andrew Obenshain, CEO of Inventiva Inventiva (Euronext Paris and Nasdaq: IVA) is advancing development of an oral treatment for metabolic dysfunction-associated steatohepatitis (MASH) with its...

October 20, 2026

Feature

AIM advancing immunology solutions for globally important diseases

AIM ImmunoTech (NYSE American: AIM) is developing Ampligen, an immune modulator with potential applications across oncology, immune disorders, and viral diseases. The company is currently focused on developing Ampligen...

October 6, 2026

Feature

Akebia challenging the status quo in kidney disease

Akebia Therapeutics (NASDAQ: AKBA) is advancing the Nobel Prize-winning science behind hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) through its commercial product, Vafseo, an oral therapy designed...

September 29, 2026

Feature

Castle guiding patient management with gene expression profiling

Castle Biosciences (NASDAQ: CSTL) is helping clinicians move beyond traditional pathology using gene expression profiling to reveal the underlying biology of a patient’s tumor, enabling more personalized treatment and...

September 22, 2026

Feature

electroCore builds on its neuromodulation platform to drive its next phase of growth

electroCore (NASDAQ: ECOR) has built a commercial-stage bioelectric medicine and wellness platform around non-invasive neuromodulation, with applications spanning prescription therapeutics, military human performance...

September 1, 2026

Feature

AINGENS transforming complex scientific and medical workflows with evidence-first integrated AI solutions

Closely held AINGENS is addressing one of healthcare’s most persistent operational challenges—the costly, laborious process of transforming scientific data into compliant, actionable content. The company developed an...

August 18, 2026

Feature

Alto disrupting the trial-and-error approach to treating neuropsychiatric disorders

Alto Neuroscience (NYSE: ANRO) is aiming to redefine the way neuropsychiatric conditions are treated through a biology-driven pipeline designed to deliver more effective treatment options. Drawing on expertise in...

August 4, 2026

Feature

In conversation with Jen Sharpe, partner, advisory services, at IntegriChain, and founder of the Revenue Analytics Collaboration

A pharmaceutical and life sciences technology, data, and consulting platform, IntegriChain delivers solutions that help companies manage the commercial and financial complexities of bringing therapies to market...

July 21, 2026

Feature

Adaptin Bio is leveraging immune cell hitchhiking to target brain tumors

Adaptin Bio (OTCQB: APTN) is advancing a novel strategy to overcome one of the most persistent challenges in neuro-oncology—delivering effective therapies across the blood-brain barrier. By leveraging the natural...

July 14, 2026

Feature

Senti Biosciences outsmarting complex disease with next-gen cell and gene therapies

Senti Biosciences (NASDAQ: SNTI) is developing a new generation of cell and gene therapies designed to bring greater precision, control, and safety to the treatment of difficult-to-treat cancers and other incurable...

July 7, 2026

Category - Feature

Subscribe